Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
János András Mótyán, Mohamed Mahdi, Gyula Hoffka, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3507-3507
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1681-1693
Open Access | Times Cited: 218
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Yuyong Zhou, Karen Anbro Gammeltoft, Line A. Ryberg, et al.
Science Advances (2022) Vol. 8, Iss. 51
Open Access | Times Cited: 163
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 45
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
Anh‐Tien Ton, Mohit Pandey, Jason R. Smith, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 11, pp. 906-919
Open Access | Times Cited: 38
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 26
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
Miklós Bege, Anikó Borbás
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 12
Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 Mpro
Jiayi Ren, Zhengfu Zhang, Yi Xia, et al.
Molecules (2025) Vol. 30, Iss. 2, pp. 351-351
Open Access
A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2
Karen Sargsyan, Karine Mazmanian, Carmay Lim
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site
Vera Jannie Elisabeth van Vliet, Nhan Huynh, Judith Palà, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 12, pp. e1011065-e1011065
Open Access | Times Cited: 23
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential
Mohammed Salah Ayoup, Mariam M. ElShafey, Hamida Abdel‐Hamid, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115272-115272
Open Access | Times Cited: 12
The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors
Ming Liu, Jihui Li, Wenqi Liu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 41
Open Access | Times Cited: 12
Resistance‐associated mutations to the anti‐SARS‐CoV‐2 agent nirmatrelvir: Selection not induction
Philippe Colson, Jérémy Delerce, Pierre Pontarotti, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 4
Recent advances in small-molecular therapeutics for COVID-19
Lei Zhong, Zhipeng Zhao, Xuerun Peng, et al.
Precision Clinical Medicine (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 21
A guide to COVID‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV‐2 infection
Drugan K. Brady, Aashi R. Gurijala, Liyu Huang, et al.
FEBS Journal (2022) Vol. 291, Iss. 8, pp. 1632-1662
Open Access | Times Cited: 19
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 3
Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
Haihai Jiang, Xiaofang Zou, Pei Zeng, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 9
Review and perspective on bioinformatics tools using machine learning and deep learning for predicting antiviral peptides
Nicolás Lefin, Lisandra Herrera-Belén, Jorge G. Farías, et al.
Molecular Diversity (2023) Vol. 28, Iss. 4, pp. 2365-2374
Closed Access | Times Cited: 9
The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus
Shaza S. Issa, С. В. Сокорнова, Roman R. Zhidkin, et al.
Plants (2022) Vol. 11, Iss. 14, pp. 1862-1862
Open Access | Times Cited: 15
Projected COVID-19 Mortality Reduction From Paxlovid Rollout
Mihir Khunte, Soryan Kumar, Joshua A. Salomon, et al.
JAMA Health Forum (2023) Vol. 4, Iss. 3, pp. e230046-e230046
Open Access | Times Cited: 8
Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
Wei Zhuang, Jiabing Xu, Ye Wu, et al.
British Journal of Clinical Pharmacology (2023) Vol. 89, Iss. 9, pp. 2830-2842
Open Access | Times Cited: 7
Hydrogels in Gene Delivery Techniques for Regenerative Medicine and Tissue Engineering
Kexing Xu, Qinmeng Zhang, Danji Zhu, et al.
Macromolecular Bioscience (2024) Vol. 24, Iss. 6
Closed Access | Times Cited: 2
Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana
Wonderful T. Choga, Ontlametse T. Bareng, Natasha O. Moraka, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 7
Open Access | Times Cited: 2
Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77
Haihai Jiang, Wen Li, Xuelan Zhou, et al.
International Journal of Biological Macromolecules (2024) Vol. 276, pp. 133706-133706
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top